IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 150.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 108,258 shares of the company's stock after buying an additional 65,050 shares during the quarter. Thrivent Financial for Lutherans owned 0.13% of IDEXX Laboratories worth $54,693,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in IDXX. Crewe Advisors LLC purchased a new position in IDEXX Laboratories during the first quarter worth about $26,000. Ridgewood Investments LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $27,000. Institutional & Family Asset Management LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at approximately $28,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in shares of IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock valued at $29,000 after buying an additional 57 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC grew its holdings in IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock worth $34,000 after acquiring an additional 60 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock traded up $0.27 during midday trading on Tuesday, reaching $420.10. 477,763 shares of the company were exchanged, compared to its average volume of 501,397. The firm's 50-day simple moving average is $467.11 and its 200-day simple moving average is $482.44. IDEXX Laboratories, Inc. has a 1 year low of $404.74 and a 1 year high of $583.39. The company has a market capitalization of $34.40 billion, a price-to-earnings ratio of 40.49, a P/E/G ratio of 3.67 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company's quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.53 earnings per share. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of recent analyst reports. BTIG Research assumed coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a "buy" rating and a $580.00 target price for the company. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a report on Thursday, October 10th. Piper Sandler restated a "neutral" rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Barclays reduced their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. lowered their price target on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of "Moderate Buy" and a consensus price target of $552.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.